Global rates of influenza and pneumococcal vaccination in multiple myeloma patients in INSIGHT MM

Total body radiation vs chemotherapy-based conditioning in children and adolescents with ALL

Evaluating the impact of daratumumab for the treatment of multiple myeloma according to cytogenetic risk

MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD response-adapted consolidation in NDMM

UKALL2011: Treatment with a tyrosine kinase inhibitor improves outcomes for patients with acute lymphoblastic leukaemia and an ABL-class fusion

Long-term disease control in multiple myeloma by in-class transitioning: A community-based study

Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma

Gut microbiome disturbance by antibiotic treatment early in life is sufficient to induce leukaemia in predisposed mice

Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma

Treating patients with multiple myeloma in the real world

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL

KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma

Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML

New CAR T therapy for relapsed and refractory ALL

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera

ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly-diagnosed AL amyloidosis

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia

The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab

Maintenance treatment in multiple myeloma: A new era

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML

Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics

AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory multiple myeloma

VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myeloid leukaemia

OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid leukaemia

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapy

CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

Patient reported outcomes for the CANDOR trial for multiple myeloma